Virtual Conference Presentation and Investor Q&A with Panna Sharma, CEO of Cancer Genetics, Inc. (NASDAQCM: CGIX), an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual, discusses the company at the RedChip Emerging Growth Showcase
Dave Gentry, host of “The RedChip Money Report: Small Stocks Big Money,” interviews Panna Sharma, CEO of Cancer Genetics (NasdaqCM: CGIX), at the NASDAQ MarketSite. Cancer Genetics, an emerging leader in DNA-based cancer diagnostics, rang the NASDAQ opening bell on August 28, 2013.
Dave Gentry interviews Panna Sharma, CEO and president of Cancer Genetics (NasdaqCM: CGIX) (formerly OTC QB: CGIX), on “The RedChip Money Report.” Cancer Genetics is an emerging leader in DNA-based cancer diagnostics. As discussed in the interview, billionaire John Pappajohn has invested $12 million in Cancer Genetics. The company uplisted to the NASDAQ Capital Market in August 2013.